Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Holding AXSM?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.96Last Year’s EPS
-$2.08Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -0.27%
|Next Earnings Date:Mar 03, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted robust revenue growth and strong sales performance for key products, alongside significant progress in the pipeline. Despite increased costs and a net loss, the strong cash position and strategic advancements suggest a positive outlook.Company Guidance
During the Axsome Therapeutics Q3 2024 earnings call, the company provided guidance showcasing strong financial performance and strategic plans. Axsome reported a milestone achievement with quarterly product revenue surpassing $100 million for the first time, translating to an annual revenue run rate of around $420 million. Key product drivers include Auvelity, which achieved $80.4 million in net sales, marking a 113% year-over-year growth, and Sunosi with $24.4 million, up 21% from the previous year. The company outlined plans to expand its sales force for Auvelity to approximately 300 representatives by Q1 2025 and is preparing for a potential commercial launch of AXS-07 for migraine treatment following a PDUFA action goal date of January 31, 2025. With a robust late-stage pipeline and a focus on expanding market access, Axsome anticipates continued growth and aims to reach cash flow positivity using its existing cash reserves of $327.3 million.Record Product Revenue
Achieved quarterly product revenue in excess of $100 million for the first time, translating to an annual revenue run rate of approximately $420 million.
Significant Revenue Growth
Total net product revenue of $104.8 million represented an 81% year-over-year increase.
Auvelity Sales Momentum
Auvelity sales increased to $80.4 million, representing 113% year-over-year growth and 24% sequential growth from Q2 2024.
Sunosi Performance
Sunosi delivered net product revenue of $24.4 million, a 21% increase compared to the same period in 2023.
Pipeline Advancements
Resubmission of NDA for AXS-07, with a PDUFA action goal date of January 31, 2025, and multiple ongoing Phase III trials expected to report results soon.
Strong Cash Position
Cash and cash equivalents totaled $327.3 million, with sufficient funds to reach cash flow positivity.
---
AXSM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AXSM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $90.98 | $99.49 | +9.35% |
| Aug 05, 2024 | $84.42 | $83.21 | -1.43% |
| May 06, 2024 | $74.80 | $75.94 | +1.52% |
| Feb 20, 2024 | $92.81 | $81.14 | -12.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Axsome Therapeutics Inc (AXSM) report earnings?
Axsome Therapeutics Inc (AXSM) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Axsome Therapeutics Inc (AXSM) earnings time?
Axsome Therapeutics Inc (AXSM) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AXSM EPS forecast?
AXSM EPS forecast for the fiscal quarter 2024 (Q4) is -$0.96.
---